BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia
Bristol Myers Squibb is shedding two clinical programs from its in-house pipeline, one from its 2023 Mirati buyout and another from a partnership with U.K. biotech Exscientia, now known as…